The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...

These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...

During a live event, Sara Nunnery, MD, MSCI, and participants discussed impressions of recent data from the ASCENT-04 and ASCENT-03 trials.

Celcuity expects to complete a rolling NDA submission for gedatolisib under the FDA RTOR program by Q4 2025. Click here to ...

It was my cool, hipster hair stylist, Dylan, who first told me that Amazons—you know, that empire of legendary women warriors ...

The FDA approved elinzanetant (Lynkuet), a new type of nonhormonal drug to treat disruptive menopausal hot flashes, Bayer ...

I read your recent column where you said that ivermectin has not been proven to be an effective treatment for cancer. I feel ...

Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...

Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.